Asia-Pacific Epirubicin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Dosage, Application, and Distribution Channel

List of Tables

The APAC epirubicin market is expected to grow from US$ 29,679.40 thousand in 2022 to US$ 37,447.28 thousand by 2028; it is estimated to grow at a CAGR of 4.0% from 2022 to 2028.

Rising Prevalence of Cancer Boosts Epirubicin Market

Epirubicin is an anthracycline drug that is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy. Further, the number of people diagnosed with liver cancer has been rising, and it is common in several parts of the region. Hence, the rising prevalence of cancer cases is driving the epirubicin market across the region.

Market Overview

The APAC epirubicin market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. The developing economies such as China, India, and Indonesia are investing substantially in infrastructure and industrial development. In APAC, China is the largest market for epirubicin. The market growth is primarily attributed to the growing pharmaceutical industry, increasing developments by the market players, and favorable regulatory policies. Further, the excessive population in China and the rising prevalence of cancer are majorly boosting the demand for cancer drugs. Also, the growing prevalence of cancer in China is likely to increase the demand for cancer treatment. As per the WHO report, in 2020, there were ~4,568,754 new cases of cancer and 3,002,899 cancer-associated deaths in China. Thus, the huge cancer patient population and product and treatment developments by the market players are expected to propel the demand for cancer vaccines in the country.

APAC Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)

APAC Epirubicin Market Segmentation

The APAC epirubicin market is segmented based on dosage, application, distribution channel, and country

Based on dosage, the APAC epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest market share in 2022. Based on application, the APAC epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held the largest market share in 2022. Based on distribution channel, the APAC epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. Based on country, the APAC epirubicin market is categorized into China, India, Japan, South Korea, Australia, and the Rest of APAC. Further, China dominated the market in 2022. Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Miracalus Pharma Pvt. Ltd., Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the APAC epirubicin market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC epirubicin market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC epirubicin market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the epirubicin market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00027251

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 APAC Epirubicin Market - By Dosage
- 1.3.2 APAC Epirubicin Market - By Application
- 1.3.3 APAC Epirubicin Market - By Distribution Channel
- 1.3.4 APAC Epirubicin Market - By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. APAC Epirubicin Market - Market Landscape

4.1 Overview
4.2 APAC PEST Analysis
4.3 Experts Opinion

5. APAC Epirubicin Market- Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Cancer
- 5.1.2 Increasing Awareness Regarding Cancer
5.2 Market Restraints
- 5.2.1 Elevated Risk of Adverse Effects due to Epirubicin
5.3 Future Trends
- 5.3.1 Increase in Number of Cancer Research Programs
5.4 Impact Analysis

6. Epirubicin Market- APAC Analysis

6.1 APAC Epirubicin Market Revenue Forecasts and Analysis

7. APAC Epirubicin Market Analysis - By Dosage

7.1 Overview
7.2 APAC Epirubicin Market, by Dosage, 2022 & 2028 (%)
7.3mg/Vial
- 7.3.1 Overview
- 7.3.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.4mg/Vial
- 7.4.1 Overview
- 7.4.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.5mg/Vial
- 7.5.1 Overview
- 7.5.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.6mg/Vial
- 7.6.1 Overview
- 7.6.2 Mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)

8. APAC Epirubicin Market Analysis - By Application

8.1 Overview
8.2 APAC Epirubicin Market, by Application, 2022 & 2028 (%)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.4 Liver Cancer
- 8.4.1 Overview
- 8.4.2 Liver Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.5 Bladder Cancer
- 8.5.1 Overview
- 8.5.2 Bladder Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others Cancer Market Revenue and Forecast to 2028 (US$ Thousand)

9. APAC Epirubicin Market Analysis - By Distribution Channel

9.1 Overview
9.2 APAC Epirubicin Market, by Distribution Channel, 2022 & 2028 (%)
9.3 Hospital Pharmacies
- 9.3.1 Overview
- 9.3.2 Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.4 Retail Pharmacies
- 9.4.1 Overview
- 9.4.2 Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.5 Online Pharmacies
- 9.5.1 Overview
- 9.5.2 Online Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)

10. APAC Epirubicin Market - Country Analysis

10.1 Overview
- 10.1.1 APAC: Epirubicin Market, by Country, 2022 & 2028 (%)
  - 10.1.1.1 China Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
    - 10.1.1.1.1 Overview
    - 10.1.1.1.2 China: Epirubicin Market - Revenue and Forecast to 2028 (US$ Thousand)
    - 10.1.1.1.3 China: Epirubicin Market, by Dosage, 2019-2028 (US$ Thousand)
    - 10.1.1.1.4 China: Epirubicin Market, by Application, 2019-2028 (US$ Thousand)
    - 10.1.1.1.5 China: Epirubicin Market, by Distribution Channel, 2019-2028 (US$ Thousand)
  - 10.1.1.2 Japan Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 Japan: Epirubicin Market - Revenue and Forecast to 2028 (US$ Thousand)
    - 10.1.1.2.3 Japan: Epirubicin Market, by Dosage, 2019-2028 (US$ Thousand)
    - 10.1.1.2.4 Japan: Epirubicin Market, by Application, 2019-2028 (US$ Thousand)
    - 10.1.1.2.5 Japan: Epirubicin Market, by Distribution Channel, 2019-2028 (US$ Thousand)
  - 10.1.1.3 India Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 India: Epirubicin Market - Revenue and Forecast to 2028 (US$ Thousand)
    - 10.1.1.3.3 India: Epirubicin Market, by Dosage, 2019-2028 (US$ Thousand)
    - 10.1.1.3.4 India: Epirubicin Market, by Application, 2019-2028 (US$ Thousand)
    - 10.1.1.3.5 India: Epirubicin Market, by Distribution Channel, 2019-2028 (US$ Thousand)
  - 10.1.1.4 South Korea Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
    - 10.1.1.4.1 Overview
    - 10.1.1.4.2 South Korea: Epirubicin Market - Revenue and Forecast to 2028 (US$ Thousand)
    - 10.1.1.4.3 South Korea: Epirubicin Market, by Dosage, 2019-2028 (US$ Thousand)
    - 10.1.1.4.4 South Korea: Epirubicin Market, by Application, 2019-2028 (US$ Thousand)
    - 10.1.1.4.5 South Korea: Epirubicin Market, by Distribution Channel, 2019-2028 (US$ Thousand)
  - 10.1.1.5 Australia Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
    - 10.1.1.5.1 Overview
    - 10.1.1.5.2 Australia: Epirubicin Market - Revenue and Forecast to 2028 (US$ Thousand)
    - 10.1.1.5.3 Australia: Epirubicin Market, by Dosage, 2019-2028 (US$ Thousand)
    - 10.1.1.5.4 Australia: Epirubicin Market, by Application, 2019-2028 (US$ Thousand)
    - 10.1.1.5.5 Australia: Epirubicin Market, by Distribution Channel, 2019-2028 (US$ Thousand)
  - 10.1.1.6 Rest of APAC Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
    - 10.1.1.6.1 Overview
    - 10.1.1.6.2 Rest of APAC: Epirubicin Market - Revenue and Forecast to 2028 (US$ Thousand)
    - 10.1.1.6.3 Rest of APAC: Epirubicin Market, by Dosage, 2019-2028 (US$ Thousand)
    - 10.1.1.6.4 Rest of APAC: Epirubicin Market, by Application, 2019-2028 (US$ Thousand)
    - 10.1.1.6.5 Rest of APAC: Epirubicin Market, by Distribution Channel, 2019-2028 (US$ Thousand)

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies
- 11.2.1 Overview

12. Company Profiles

12.1 Pfizer Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Teva Pharmaceutical Industries Ltd.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Salius Pharma Pvt Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Mylan N.V.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Hikma Pharmaceuticals PLC
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Fresenius Kabi AG
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Miracalus Pharma Pvt. Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms